| Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery | Phase 2 | ECOG-ACRIN Cancer Research Group | <1 mi |
| Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects | — | Alliance for Clinical Trials in Oncology | <1 mi |
| Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease | Phase 2/3 | NRG Oncology | <1 mi |
| Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study | Phase 2 | NRG Oncology | <1 mi |
| Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging | Phase 3 | ECOG-ACRIN Cancer Research Group | <1 mi |
| Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Comparing Radiation Therapy to Usual Care for Patients With High-Risk Bone Asymptomatic Metastases, PREEMPT Trial | Phase 3 | NRG Oncology | <1 mi |
| Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer | Phase 2/3 | National Cancer Institute (NCI) | <1 mi |
| Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment | Phase 3 | SWOG Cancer Research Network | <1 mi |
| Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial | Phase 3 | ECOG-ACRIN Cancer Research Group | <1 mi |
| APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer | Phase 3 | SWOG Cancer Research Network | <1 mi |
| Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations | Phase 2 | Alliance for Clinical Trials in Oncology | <1 mi |
| mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers | Phase 2 | SWOG Cancer Research Network | <1 mi |
| Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation | Phase 2 | SWOG Cancer Research Network | <1 mi |
| Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps | N/A | NRG Oncology | <1 mi |
| Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas | Phase 2 | Alliance for Clinical Trials in Oncology | <1 mi |
| Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer | Phase 3 | NRG Oncology | <1 mi |
| Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors | Phase 3 | Children's Oncology Group | <1 mi |
| Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma | Phase 3 | ECOG-ACRIN Cancer Research Group | <1 mi |
| Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials | N/A | Eastern Cooperative Oncology Group | <1 mi |
| Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence | Phase 3 | Stemline Therapeutics, Inc. | <1 mi |
| S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer | N/A | SWOG Cancer Research Network | <1 mi |
| Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 | Phase 3 | NRG Oncology | <1 mi |
| De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) | Phase 3 | NRG Oncology | <1 mi |
| S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity | Phase 3 | SWOG Cancer Research Network | <1 mi |
| Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer | Phase 3 | SWOG Cancer Research Network | <1 mi |
| Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer | Phase 2/3 | SWOG Cancer Research Network | <1 mi |
| Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) | Phase 2 | SWOG Cancer Research Network | <1 mi |
| Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection | — | Alliance for Clinical Trials in Oncology | <1 mi |
| Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors | Phase 2 | SWOG Cancer Research Network | <1 mi |
| Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer | Phase 2/3 | National Cancer Institute (NCI) | <1 mi |
| Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study | Phase 2/3 | National Cancer Institute (NCI) | <1 mi |
| Comparing Brief Behavioral Therapy (BBT-CI) and Healthy Eating Education Learning (HEAL) for Cancer-Related Sleep Problems While Receiving Cancer Treatment | Phase 3 | University of Rochester NCORP Research Base | <1 mi |
| An Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study | — | University of Rochester NCORP Research Base | <1 mi |
| A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer | Phase 3 | Seagen, a wholly owned subsidiary of Pfizer | <1 mi |
| A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases | Phase 2 | SWOG Cancer Research Network | <1 mi |
| Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors | — | ECOG-ACRIN Cancer Research Group | <1 mi |
| Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| Cost Communication and Financial Navigation in Cancer Patients (COSTCOM) | N/A | ECOG-ACRIN Cancer Research Group | <1 mi |
| Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response | Phase 3 | Canadian Cancer Trials Group | <1 mi |
| Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer | Phase 2 | Protara Therapeutics | <1 mi |
| An Internet-based Program to Help Cancer Survivors Manage Pain | N/A | Wake Forest University Health Sciences | <1 mi |
| Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial | Phase 2 | NRG Oncology | <1 mi |
| Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| The Immune System's Response to Young Women's Breast Cancer | — | University of Colorado, Denver | <1 mi |
| A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer | Phase 1/2 | Pfizer | <1 mi |
| Mobile Health for Adherence in Breast Cancer Patients | N/A | ECOG-ACRIN Cancer Research Group | <1 mi |
| Breast Cancer Patient Engagement With Patient Reported Outcome Measure Survey | N/A | University of Colorado, Denver | <1 mi |
| Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors | N/A | NRG Oncology | <1 mi |
| Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer | Phase 3 | NRG Oncology | <1 mi |
| A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Janssen Research & Development, LLC | <1 mi |
| LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia | — | University of Rochester | <1 mi |
| Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion | Phase 1 | Bristol-Myers Squibb | <1 mi |
| Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 | Phase 2/3 | Mirati Therapeutics Inc. | <1 mi |
| Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation | Phase 2 | Mirati Therapeutics Inc. | <1 mi |
| Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics | — | Wake Forest University Health Sciences | <1 mi |
| The Vanguard Study: Testing a New Way to Screen for Cancer | N/A | National Cancer Institute (NCI) | <1 mi |
| Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer | Phase 3 | NRG Oncology | <1 mi |
| Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| A Lifetime Partnership With Patients Who Have or May be at Risk of Having Cancer | — | University of Colorado, Denver | <1 mi |
| A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer | Phase 3 | Canadian Cancer Trials Group | <1 mi |
| A Novel Patient Decision Aid for Surgical Treatment Options in Early-Stage Breast Cancer | N/A | University of Colorado, Denver | <1 mi |
| The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study | Phase 3 | American Society of Clinical Oncology | <1 mi |
| Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products | — | Medtronic | <1 mi |
| Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) | Phase 3 | AstraZeneca | <1 mi |
| Left vs Left Randomized Clinical Trial | N/A | Baylor College of Medicine | <1 mi |
| A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation | Phase 3 | Novo Nordisk A/S | <1 mi |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | — | Massive Bio, Inc. | <1 mi |
| "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder" | Phase 3 | Cybin IRL Limited | <1 mi |
| Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC | Phase 3 | RenovoRx | <1 mi |
| Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles) | — | GT Medical Technologies, Inc. | <1 mi |
| A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease | Phase 3 | AstraZeneca | <1 mi |
| A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer | Phase 3 | Ferring Pharmaceuticals | <1 mi |
| A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer | Phase 3 | Celgene | <1 mi |
| MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles | — | Agendia | <1 mi |
| IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | Phase 2/3 | IDEAYA Biosciences | <1 mi |
| Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells | Phase 2/3 | Celgene | <1 mi |
| Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma | Phase 3 | Children's Oncology Group | <1 mi |
| Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma | Phase 1 | Marker Therapeutics, Inc. | <1 mi |
| A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML | Phase 1 | Kura Oncology, Inc. | <1 mi |
| Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer | Phase 3 | Bayer | <1 mi |
| A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors | Phase 1 | MediLink Therapeutics (Suzhou) Co., Ltd. | <1 mi |
| Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01) | Phase 1/2 | Cellectis S.A. | <1 mi |
| A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations | Phase 2 | Sameek Roychowdhury | <1 mi |
| Pragmatic Trial of Metformin for Glucose Intolerance or Increased BMI in Prostate Cancer Patients | Early 1 | University of Colorado, Denver | <1 mi |
| A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT | Phase 2 | Children's Oncology Group | <1 mi |
| DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors | Phase 1 | DynamiCure Biotechnology | <1 mi |
| A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation | Phase 3 | European Myeloma Network B.V. | <1 mi |
| A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | Phase 2 | Astellas Pharma Global Development, Inc. | <1 mi |
| A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy | Phase 3 | Lyell Immunopharma, Inc. | <1 mi |
| A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations | Phase 3 | Children's Oncology Group | <1 mi |
| Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma | Phase 3 | Children's Oncology Group | <1 mi |
| Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy | Phase 3 | Children's Oncology Group | <1 mi |
| A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma | Phase 2/3 | National Cancer Institute (NCI) | <1 mi |
| Project: Every Child for Younger Patients With Cancer | — | Children's Oncology Group | <1 mi |
| A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) | — | Center for International Blood and Marrow Transplant Research | <1 mi |
| Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies | — | Children's Oncology Group | <1 mi |
| A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) | Phase 1 | Kura Oncology, Inc. | <1 mi |
| Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) | Phase 3 | Children's Oncology Group | <1 mi |
| Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia | Phase 2 | Children's Oncology Group | <1 mi |
| The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study | Phase 1/2 | PedAL BCU, LLC | <1 mi |
| A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors | Phase 1 | ArriVent BioPharma, Inc. | <1 mi |
| A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma | Phase 1/2 | AstraZeneca | <1 mi |
| Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER | Phase 2 | Canadian Cancer Trials Group | <1 mi |
| Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer | Phase 3 | Children's Oncology Group | <1 mi |
| A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer | Phase 3 | Eli Lilly and Company | <1 mi |
| A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events | N/A | Cleerly, Inc. | <1 mi |
| Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76) | Phase 3 | Anthos Therapeutics, Inc. | <1 mi |
| Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus | Phase 3 | AbbVie | <1 mi |
| A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1) | Phase 1 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | <1 mi |
| A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus | Phase 3 | AstraZeneca | <1 mi |
| A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS) | — | TG Therapeutics, Inc. | <1 mi |
| A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2) | Phase 1 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | <1 mi |
| A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | Phase 3 | Jazz Pharmaceuticals | <1 mi |
| First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer | Phase 1 | OnKure, Inc. | <1 mi |
| A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) | Phase 2/3 | Bristol-Myers Squibb | <1 mi |
| OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer | Phase 3 | Olema Pharmaceuticals, Inc. | <1 mi |
| A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors | Phase 1 | Eli Lilly and Company | <1 mi |
| Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma | Phase 3 | Children's Oncology Group | <1 mi |
| Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma | Phase 3 | Children's Oncology Group | <1 mi |
| QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations | Phase 1 | Quanta Therapeutics | <1 mi |
| A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | Phase 1/2 | Hoffmann-La Roche | <1 mi |
| A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge) | Phase 3 | Definium Therapeutics US, Inc. | <1 mi |
| Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy | Phase 2 | BioNTech SE | <1 mi |
| A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma | Phase 1/2 | Janssen Research & Development, LLC | <1 mi |
| A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors | Phase 1 | OnCusp Therapeutics, Inc. | <1 mi |
| Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) | Phase 2/3 | BicycleTx Limited | <1 mi |
| A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors | Phase 1 | Avistone Biotechnology Co., Ltd. | <1 mi |
| A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors | Phase 1/2 | Regeneron Pharmaceuticals | <1 mi |
| A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors | Phase 1/2 | Eikon Therapeutics | <1 mi |
| A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies | Phase 1 | Kumquat Biosciences Inc. | <1 mi |
| Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma | Phase 2 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | <1 mi |
| JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors | Phase 1 | Jazz Pharmaceuticals | <1 mi |
| A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors | Phase 1 | Context Therapeutics Inc. | <1 mi |
| A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | Phase 1/2 | BioInvent International AB | <1 mi |
| Study of PYX-201 in Solid Tumors | Phase 1 | Pyxis Oncology, Inc | <1 mi |
| A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer | Phase 3 | Amgen | <1 mi |
| A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies | Phase 1 | Kumquat Biosciences Inc. | <1 mi |
| A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1) | Phase 1/2 | Nuvalent Inc. | <1 mi |
| A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) | Phase 2 | Novartis Pharmaceuticals | <1 mi |
| A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201) | Phase 2 | Nurix Therapeutics, Inc. | <1 mi |
| A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors | Phase 1 | Genentech, Inc. | <1 mi |
| Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC | Phase 3 | Novartis Pharmaceuticals | <1 mi |
| Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma | Phase 2 | SCRI Development Innovations, LLC | <1 mi |
| An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01) | Phase 1/2 | Novartis Pharmaceuticals | <1 mi |
| A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors | Phase 1/2 | Corbus Pharmaceuticals Inc. | <1 mi |
| (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma | Phase 2 | IDEAYA Biosciences | <1 mi |
| This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors | Phase 1 | ABL Bio, Inc. | <1 mi |
| Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML | Phase 3 | Kura Oncology, Inc. | <1 mi |
| A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer | Phase 2 | BioNTech SE | <1 mi |
| Neuroblastoma Maintenance Therapy Trial | Phase 2 | Giselle Sholler | <1 mi |
| Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors | Phase 1 | Vaxiion Therapeutics | <1 mi |
| Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM | Phase 2 | Massachusetts General Hospital | <1 mi |
| Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions | Phase 1/2 | IDEAYA Biosciences | <1 mi |
| Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma | Phase 1 | AbbVie | <1 mi |
| Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL | Phase 2 | Etan Orgel | <1 mi |
| Connect for Cancer Prevention Study (Connect) | — | National Cancer Institute (NCI) | <1 mi |
| A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors | Phase 1 | Sapience Therapeutics | <1 mi |
| First In Human Study of CX-2051 in Advanced Solid Tumors | Phase 1 | CytomX Therapeutics | <1 mi |
| A Study of ASP3082 in Adults With Advanced Solid Tumors | Phase 1 | Astellas Pharma Inc | <1 mi |
| American Hepato-Pancreato-Biliary Association (AHPBA) Pancreatic Irreversible Electroporation (IRE) Registry | — | University of Louisville | <1 mi |
| A Study of CTD402 in T-ALL/LBL Patients | Phase 1/2 | BIOHENG THERAPEUTICS US LLC | <1 mi |
| A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101) | Phase 1 | GlaxoSmithKline | <1 mi |
| Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET | Phase 3 | Novartis Pharmaceuticals | <1 mi |
| CER-1236 in Patients With Acute Myeloid Leukemia (AML) | Phase 1 | CERo Therapeutics Holdings, Inc. | <1 mi |
| MB-105 in Patients With CD5 Positive T-cell Lymphoma | Phase 2 | March Biosciences Inc | <1 mi |
| A Phase 1 Study of BHV-1530 in Advanced Solid Tumors | Phase 1 | Biohaven Therapeutics Ltd. | <1 mi |
| Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma | Phase 2 | SCRI Development Innovations, LLC | <1 mi |
| A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer | Phase 1/2 | GlaxoSmithKline | <1 mi |
| A Study of HLD-0915 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) | Phase 1/2 | Halda Therapeutics OpCo, Inc. | <1 mi |
| Selinexor and Backbone Treatments of Multiple Myeloma Patients | Phase 1/2 | Karyopharm Therapeutics Inc | <1 mi |
| A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors | Phase 1 | Nested Therapeutics, Inc | <1 mi |
| First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor. | Phase 1/2 | Corbus Pharmaceuticals Inc. | <1 mi |
| A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies | Phase 1 | Kumquat Biosciences Inc. | <1 mi |
| Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors | Phase 1 | InSilico Medicine Hong Kong Limited | <1 mi |
| A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815 | Phase 1 | Jazz Pharmaceuticals | <1 mi |
| A Global Study of the PETAL Consortium | — | Massachusetts General Hospital | <1 mi |
| Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Phase 1 | Kura Oncology, Inc. | <1 mi |
| A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract | Phase 3 | Eli Lilly and Company | <1 mi |
| A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma | Phase 3 | Kite, A Gilead Company | <1 mi |
| Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors | Phase 1/2 | Daiichi Sankyo | <1 mi |
| Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma | Phase 1/2 | Novelwise Pharmaceutical Corporation | <1 mi |
| A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis | Phase 1 | Janssen Research & Development, LLC | <1 mi |
| A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms | Phase 1 | Incyte Corporation | <1 mi |
| JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation | Phase 1/2 | Jacobio Pharmaceuticals Co., Ltd. | <1 mi |
| A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study | — | M.D. Anderson Cancer Center | <1 mi |
| Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia | N/A | Massachusetts General Hospital | <1 mi |
| A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation | Phase 1/2 | Sumitomo Pharma America, Inc. | <1 mi |
| A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies | Phase 1 | Accutar Biotechnology Inc | <1 mi |
| ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR) | Phase 1 | Acepodia Biotech, Inc. | <1 mi |
| This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. | Phase 3 | Pfizer | <1 mi |
| A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies | Phase 1 | Seagen, a wholly owned subsidiary of Pfizer | <1 mi |
| A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation | Phase 1/2 | D3 Bio (Wuxi) Co., Ltd | <1 mi |
| Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors | Phase 1 | Acrivon Therapeutics | <1 mi |
| A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC) | Phase 2 | SCRI Development Innovations, LLC | <1 mi |
| Barrett's Esophagitis in Anorexia Nervosa Binge/Purge Subtype | — | Denver Health and Hospital Authority | <1 mi |
| SynKIR-310 for Relapsed/Refractory B-NHL | Phase 1 | Verismo Therapeutics | <1 mi |
| A Clinical Study of YL205 in Patients With Advanced Solid Tumors | Phase 1/2 | MediLink Therapeutics (Suzhou) Co., Ltd. | <1 mi |
| A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma | Phase 1 | AstraZeneca | <1 mi |
| A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies | Phase 1 | Nurix Therapeutics, Inc. | <1 mi |
| Study of LYL314 in Aggressive Large B-Cell Lymphoma | Phase 1/2 | Lyell Immunopharma, Inc. | <1 mi |
| A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies | Phase 1 | Nurix Therapeutics, Inc. | <1 mi |
| A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma | Phase 1 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | <1 mi |
| Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) | Phase 1/2 | Vironexis Biotherapeutics Inc. | <1 mi |
| Immuno-PRISM (PRecision Intervention Smoldering Myeloma) | Phase 2 | Irene Ghobrial, MD | <1 mi |
| A Study to Evaluate Preventive Treatments for Talquetamab-related Oral Toxicity | Phase 2 | Janssen Research & Development, LLC | <1 mi |
| A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | Phase 2/3 | AbbVie | <1 mi |
| Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) | Phase 1/2 | Juno Therapeutics, a Subsidiary of Celgene | <1 mi |
| Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) | Phase 1/2 | Phanes Therapeutics | <1 mi |
| Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer | Phase 3 | Ferring Pharmaceuticals | <1 mi |
| A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer | Phase 2 | Eli Lilly and Company | <1 mi |
| An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. | Phase 3 | Novartis Pharmaceuticals | <1 mi |
| Knee Related Subchondral Bone Lesions Treated With IOBP | — | Arthrex, Inc. | <1 mi |
| A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment | Phase 1/2 | Regeneron Pharmaceuticals | <1 mi |
| A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies | Phase 1 | MacroGenics | <1 mi |
| CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors | Phase 1/2 | Crescent Biopharma, Inc. | <1 mi |
| A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1) | Phase 1 | Nuvalent Inc. | <1 mi |
| Exogenous and Endogenous Risk Factors for Early-onset Colorectal Cancer | — | San Raffaele University | <1 mi |
| AMT-116 in Patients With Advanced Solid Tumors | Phase 1 | Multitude Therapeutics Inc. | <1 mi |
| A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia | Phase 1/2 | Astellas Pharma Global Development, Inc. | <1 mi |
| Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL | Phase 2 | Allogene Therapeutics | <1 mi |
| Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies | Phase 1 | Therapeutic Advances in Childhood Leukemia Consortium | <1 mi |
| An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | Phase 2 | Novartis Pharmaceuticals | <1 mi |
| Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) | Phase 2 | Merck Sharp & Dohme LLC | <1 mi |
| A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib | Phase 1/2 | AbbVie | <1 mi |
| Sequential Therapy in Multiple Myeloma Guided by MRD Assessments | Phase 2 | University of Alabama at Birmingham | <1 mi |
| Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML | Phase 3 | Daiichi Sankyo | <1 mi |
| A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors | Phase 1/2 | Crinetics Pharmaceuticals Inc. | <1 mi |
| QTX3034 in Patients With KRAS G12D Mutation | Phase 1 | Quanta Therapeutics | <1 mi |
| A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors | Phase 1/2 | Artios Pharma Ltd | <1 mi |
| APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML | Phase 1 | Aptevo Therapeutics | <1 mi |
| A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis) | Phase 1/2 | Regeneron Pharmaceuticals | <1 mi |
| A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas | Phase 1/2 | Step Pharma, SAS | <1 mi |
| A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel | Phase 1/2 | Iovance Biotherapeutics, Inc. | <1 mi |
| A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer | Phase 1/2 | Pfizer | <1 mi |
| A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors | Phase 1/2 | Hutchmed | <1 mi |
| A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor | Phase 1 | Abbisko Therapeutics Co, Ltd | <1 mi |
| Project Dulce for Arab Americans With Type 2 Diabetes | N/A | Scripps Whittier Diabetes Institute | <1 mi |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus | Phase 2 | Ascletis Pharma (China) Co., Limited | <1 mi |
| DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study, a Randomized, Placebo-controlled, Cross-over Study With Ertugliflozin in People With Type 2 Diabetes | Phase 4 | Amsterdam UMC, location VUmc | <1 mi |
| TrialNet Pathway to Prevention of T1D | — | University of South Florida | <1 mi |
| CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial | Phase 2 | Jason Sperry | <1 mi |
| A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS) | Phase 3 | Eli Lilly and Company | <1 mi |
| Study of WAL0921 in Patients With Glomerular Kidney Diseases | Phase 2 | Walden Biosciences | <1 mi |
| ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response | Phase 2 | ACADIA Pharmaceuticals Inc. | <1 mi |
| GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder | Phase 2 | Syndeio Biosciences, Inc | <1 mi |
| A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder | Phase 2 | Janssen Research & Development, LLC | <1 mi |
| Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA) | Phase 2 | atai Therapeutics, Inc. | <1 mi |
| In-person vs. Virtual Delivery of a Group-based Prevention of Postpartum Depression | N/A | University of Denver | <1 mi |
| Parenting Skills Group for Mothers With Postpartum Depression | N/A | University of Colorado, Denver | <1 mi |
| International Weight Control Registry | — | Tufts University | <1 mi |
| VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) | Phase 3 | Viking Therapeutics, Inc. | <1 mi |
| Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial | N/A | Edwards Lifesciences | <1 mi |
| Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis | Phase 2/3 | CSL Behring | <1 mi |
| ET1 Concentration, Metabolic Pathway Activation, and Pulmonary Blood Flow in Infants Undergoing Superior Cavo-Pulmonary Anastomosis | — | University of Colorado, Denver | <1 mi |
| Optimizing Heart Failure Therapies Among Patients With Limited Access in Denver | N/A | Denver Health and Hospital Authority | <1 mi |
| MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation | N/A | University of California, San Francisco | <1 mi |
| RADIQAL Study (Radiation Dose and Image Quality Trial) | N/A | Philips Clinical & Medical Affairs Global | <1 mi |
| Optimal Ventilation for Cardiac Arrest | N/A | Children's Hospital of Philadelphia | <1 mi |
| Fontan Udenafil Exercise Longitudinal Assessment Trial - 2 | Phase 3 | Mezzion Pharma Co. Ltd | <1 mi |
| Using AI Text Messaging to Improve AHA's Life's Essential 8 Health Behaviors | N/A | University of Colorado, Denver | <1 mi |
| TECTONIC CAD IVL IDE Study | N/A | Abbott Medical Devices | <1 mi |
| Bright Light Exposure in Surgical Patients | N/A | University of Colorado, Denver | <1 mi |
| Slow Heart Registry of Fetal Immune-mediated High Degree Heart Block | — | The Hospital for Sick Children | <1 mi |
| Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma | Phase 4 | Regeneron Pharmaceuticals | <1 mi |
| Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma | Phase 3 | AstraZeneca | <1 mi |
| Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment | Phase 3 | AstraZeneca | <1 mi |
| Study to Improve Deployment Related Asthma by Using L-Citrulline Supplementation | Phase 2 | University of Colorado, Denver | <1 mi |
| Nipocalimab in Moderate to Severe Sjogren's Disease | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome | Phase 3 | Bristol-Myers Squibb | <1 mi |
| Exactech Shoulder Post Market Clinical Follow-up Study | — | Exactech | <1 mi |
| G7 Acetabular System With Vivacit-E or Longevity Liner PMCF Study | N/A | Zimmer Biomet | <1 mi |
| The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis | N/A | University of Colorado, Denver | <1 mi |
| A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines | Phase 3 | Takeda | <1 mi |
| Restoration Anatomic Acetabular Shell Revision Study | N/A | Stryker Orthopaedics | <1 mi |
| Chronic Pain in Rheumatoid Arthritis | — | Northwestern University | <1 mi |
| A Study of Dotinurad Versus Allopurinol in Participants With Gout | Phase 3 | Crystalys Therapeutics | <1 mi |
| AETOS Shoulder System | — | Smith & Nephew, Inc. | <1 mi |
| SMR Stemless Reverse Vs SMR Reverse Shoulder System | N/A | Limacorporate S.p.a | <1 mi |
| SPIROMICS Study of Early COPD Progression (SOURCE) | — | University of Massachusetts, Worcester | <1 mi |
| Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD) | Phase 2 | Connect Biopharm LLC | <1 mi |
| Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD | Phase 2 | Johns Hopkins University | <1 mi |
| PRagmatic EVAluation of a Quality Improvement Program for People Living With Modifiable High-risk COPD. | N/A | Observational and Pragmatic Research Institute | <1 mi |
| A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage) | Phase 3 | Definium Therapeutics US, Inc. | <1 mi |
| Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder | Phase 3 | Vanda Pharmaceuticals | <1 mi |
| Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4) | Phase 3 | VistaGen Therapeutics, Inc. | <1 mi |
| A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus | Phase 2/3 | Biogen | <1 mi |
| TSC Biosample Repository and Natural History Database | — | National Tuberous Sclerosis Association | <1 mi |
| A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101 | — | Kyverna Therapeutics | <1 mi |
| A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors | Phase 1 | Alterome Therapeutics, Inc. | <1 mi |
| A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors | Phase 1 | Normunity AccelCo, Inc. | <1 mi |
| ASPEN-09: A Study of Evorpacept in Combination With Anti-cancer Therapies in Advanced / Metastatic Malignancies | Phase 1/2 | ALX Oncology Inc. | <1 mi |
| Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects | Phase 3 | Greenwich LifeSciences, Inc. | <1 mi |
| A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors | Phase 1 | NiKang Therapeutics, Inc. | <1 mi |
| A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors. | Phase 1/2 | Eikon Therapeutics | <1 mi |
| Phase IIIb Study of Ribociclib + ET in Early Breast Cancer | Phase 3 | Novartis Pharmaceuticals | <1 mi |
| Gene Therapy for HER-Positive Cancer (SENTRY-HER2) | Phase 1/2 | Vironexis Biotherapeutics Inc. | <1 mi |
| First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer | Phase 1 | Relay Therapeutics, Inc. | <1 mi |
| Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease | Phase 3 | Pfizer | <1 mi |
| A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer | Phase 2 | Jazz Pharmaceuticals | <1 mi |
| Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors | Phase 1/2 | Tasca Therapeutics | <1 mi |
| Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors | Phase 2 | Iovance Biotherapeutics, Inc. | <1 mi |
| Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors | Phase 2 | Aadi Bioscience, Inc. | <1 mi |
| Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC | Phase 3 | Nuvalent Inc. | <1 mi |
| BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors | Phase 1 | BeiGene | <1 mi |
| A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors | Phase 1 | Conjupro Biotherapeutics, Inc. | <1 mi |
| A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer | Phase 1/2 | IDEAYA Biosciences | <1 mi |
| A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | Phase 1 | Incyte Corporation | <1 mi |
| AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104). | Phase 1 | Amgen | <1 mi |
| AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001) | Phase 1/2 | Avenzo Therapeutics, Inc. | <1 mi |
| A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors | Phase 1/2 | Marengo Therapeutics, Inc. | <1 mi |
| A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer | Phase 1 | BeiGene | <1 mi |
| CT-95 in Advanced Cancers Associated With Mesothelin Expression | Phase 1 | Context Therapeutics Inc. | <1 mi |
| MYLUNG Consortium Part 3: Observational Study | — | US Oncology Research | <1 mi |
| A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers | Phase 1 | Nuvectis Pharma, Inc. | <1 mi |
| KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors | Phase 1 | Kura Oncology, Inc. | <1 mi |
| Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients | Phase 1/2 | Tango Therapeutics, Inc. | <1 mi |
| A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) | Phase 3 | Mirati Therapeutics Inc. | <1 mi |
| MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors | Phase 1 | Eli Lilly and Company | <1 mi |
| Safety and Durability of Sirolimus for Treatment of LAM | — | University of Cincinnati | <1 mi |
| A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer | Phase 1 | Sutro Biopharma, Inc. | <1 mi |
| Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors | Phase 1/2 | Tango Therapeutics, Inc. | <1 mi |
| A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS | Phase 3 | AstraZeneca | <1 mi |
| A Phase 2 Study of AMG 193 in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201) | Phase 2 | Amgen | <1 mi |
| A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors | Phase 1 | NiKang Therapeutics, Inc. | <1 mi |
| National Cancer Institute "Cancer Moonshot Biobank" | — | National Cancer Institute (NCI) | <1 mi |
| A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) | Phase 1/2 | Phanes Therapeutics | <1 mi |
| A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors | Phase 1 | IDEAYA Biosciences | <1 mi |
| A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors | Phase 1 | Eli Lilly and Company | <1 mi |
| Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors | Phase 1 | InSilico Medicine Hong Kong Limited | <1 mi |
| Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 | Phase 1/2 | Simcha IL-18, Inc. | <1 mi |
| A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors | Phase 1 | Eli Lilly and Company | <1 mi |
| A Study of DF6002 Alone and in Combination With Nivolumab | Phase 1 | Dragonfly Therapeutics | <1 mi |
| The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | Phase 1/2 | PMV Pharmaceuticals, Inc | <1 mi |
| TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers | Phase 1 | Tizona Therapeutics, Inc | <1 mi |
| SMP-3124LP in Adults With Advanced Solid Tumors | Phase 1/2 | Sumitomo Pharma America, Inc. | <1 mi |
| Study of Novel Treatment Combinations in Patients With Lung Cancer | Phase 2 | Gilead Sciences | <1 mi |
| A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas | Phase 1 | Dren Bio | <1 mi |
| A First-in-human Study to Learn How Safe BAY 3713372 is and How it Works in Participants With MTAP-deleted Solid Tumors | Phase 1/2 | Bayer | <1 mi |
| A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies | Phase 1 | RasCal Therapeutics, Inc. | <1 mi |
| A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies | Phase 1/2 | GV20 Therapeutics | <1 mi |
| Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema | Phase 2 | Sanofi | <1 mi |
| PiMZ Longitudinal Cohort (PiMZ Logic) | — | Columbia University | <1 mi |
| A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4) | Phase 3 | Mirum Pharmaceuticals, Inc. | <1 mi |
| A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis | Phase 2 | Genentech, Inc. | <1 mi |
| Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma | Phase 1 | Nammi Therapeutics Inc | <1 mi |
| Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors | Phase 1/2 | ModeX Therapeutics, An OPKO Health Company | <1 mi |
| Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor | Phase 3 | OSE Immunotherapeutics | 5 mi |
| Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | Phase 3 | AstraZeneca | 5 mi |
| Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma. | Phase 2 | Sanofi | 5 mi |
| Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain | Phase 2 | Dogwood Therapeutics Inc. | 5 mi |
| Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations | Phase 3 | AstraZeneca | 5 mi |
| Volrustomig Priming Regimens Exploratory Phase II Platform Study | Phase 2 | AstraZeneca | 5 mi |
| DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors | Phase 2 | DualityBio Inc. | 5 mi |
| Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) | Phase 3 | Merck Sharp & Dohme LLC | 5 mi |
| A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) | Phase 3 | Merck Sharp & Dohme LLC | 5 mi |
| Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC | Phase 2 | CG Oncology, Inc. | 5 mi |
| S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer | Phase 3 | SWOG Cancer Research Network | 5 mi |
| Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy | Phase 3 | Rocky Mountain Cancer Centers | 5 mi |
| A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis | Phase 3 | Sumitomo Pharma Switzerland GmbH | 5 mi |
| A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer | Phase 3 | Janssen Research & Development, LLC | 5 mi |
| Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T | Phase 2 | Dendreon | 5 mi |
| LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve | Phase 1/2 | enGene, Inc. | 5 mi |
| A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). | Phase 3 | Pfizer | 5 mi |
| ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer | Phase 2 | Zenith Epigenetics | 5 mi |
| A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer | Phase 3 | Janssen Research & Development, LLC | 5 mi |
| Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer | N/A | Alliance for Clinical Trials in Oncology | 5 mi |
| A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC) | Phase 3 | Janssen Research & Development, LLC | 5 mi |
| Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations | Phase 3 | SWOG Cancer Research Network | 5 mi |
| Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents | Phase 3 | AstraZeneca | 5 mi |
| Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors | Phase 3 | SWOG Cancer Research Network | 5 mi |
| A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy | Phase 2 | Boehringer Ingelheim | 5 mi |
| Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase | N/A | University of Alabama, Tuscaloosa | 5 mi |
| Product Surveillance Registry | — | Medtronic | 5 mi |
| Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) | Phase 2 | Bristol-Myers Squibb | 5 mi |
| A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | Phase 3 | Teva Branded Pharmaceutical Products R&D, Inc. | 5 mi |
| Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype | Phase 3 | Sanofi | 5 mi |
| A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease | Phase 2 | AstraZeneca | 5 mi |
| ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab | Phase 3 | Alliance for Clinical Trials in Oncology | 5 mi |
| A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation | Phase 3 | AstraZeneca | 5 mi |
| Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer | Phase 3 | Alliance for Clinical Trials in Oncology | 5 mi |
| A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis | Phase 3 | Ipsen | 6 mi |
| A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) | Phase 3 | Erasca, Inc. | 6 mi |
| A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma | Phase 2/3 | Replimune Inc. | 6 mi |
| Neoadjuvant Darovasertib in Primary Uveal Melanoma | Phase 3 | IDEAYA Biosciences | 6 mi |
| A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) | Phase 3 | Regeneron Pharmaceuticals | 6 mi |
| Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera | Phase 3 | Italfarmaco | 6 mi |
| A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes | Phase 3 | Novo Nordisk A/S | 6 mi |
| Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes | Phase 3 | vTv Therapeutics | 6 mi |
| A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD | Phase 3 | Annovis Bio Inc. | 6 mi |
| Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin | Phase 3 | AstraZeneca | 6 mi |
| A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations | Phase 3 | Teva Branded Pharmaceutical Products R&D LLC | 6 mi |
| A Study to Evaluate Solriktug in Adult Participants With Asthma | Phase 2 | Uniquity One (UNI) | 6 mi |
| A Study to Evaluate Solrikitug in Participants With COPD (ZION) | Phase 2 | Uniquity One (UNI) | 6 mi |
| A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD) | Phase 2 | AskBio Inc | 6 mi |
| A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease | Phase 2 | TrueBinding, Inc. | 6 mi |
| To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications | Phase 3 | Cerevance | 6 mi |
| Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL) | Phase 1/2 | Prevail Therapeutics | 6 mi |
| A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease | Phase 3 | Hoffmann-La Roche | 6 mi |
| A Study of Buntanetap in Participants With PD | Phase 2/3 | Annovis Bio Inc. | 6 mi |
| A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment | — | Ipsen | 6 mi |
| A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) | Phase 3 | Inventiva Pharma | 6 mi |
| A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) | Phase 3 | Eli Lilly and Company | 6 mi |
| RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD) | Phase 2 | Altimmune, Inc. | 6 mi |
| A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH | Phase 3 | Akero Therapeutics, Inc | 6 mi |
| LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis | Phase 3 | Boehringer Ingelheim | 6 mi |
| LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis | Phase 3 | Boehringer Ingelheim | 6 mi |
| The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) | Phase 3 | Eli Lilly and Company | 7 mi |
| Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease) | Phase 3 | Endo Pharmaceuticals | 7 mi |
| A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) | Phase 3 | Merck Sharp & Dohme LLC | 7 mi |
| Phase 2/3 Study of KPL-387 in Recurrent Pericarditis | Phase 2/3 | Kiniksa Pharmaceuticals International, plc | 7 mi |
| A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE) | Phase 2 | Immunovant Sciences GmbH | 8 mi |
| Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus | Phase 2 | University of Colorado, Denver | 8 mi |
| A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma | Phase 1 | HiberCell, Inc. | 8 mi |
| A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) | Phase 3 | DualityBio Inc. | 8 mi |
| Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations | Phase 1/2 | AbbVie | 8 mi |
| Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations. | — | University of Colorado, Denver | 8 mi |
| Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 | Phase 3 | Summit Therapeutics | 8 mi |
| Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial | Phase 3 | NRG Oncology | 8 mi |
| A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer | N/A | NRG Oncology | 8 mi |
| Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer | Phase 3 | National Cancer Institute (NCI) | 8 mi |
| NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Phase 1/2 | University of Colorado, Denver | 8 mi |
| Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers | Phase 2 | NRG Oncology | 8 mi |
| Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer | Phase 3 | NRG Oncology | 8 mi |
| Improving Care for Rural Patients With Solid Tumors | N/A | University of Colorado, Denver | 8 mi |
| A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) | Phase 1/2 | Hoffmann-La Roche | 8 mi |
| The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation | Phase 3 | Johns Hopkins University | 8 mi |
| Real-world Experience of Catheter Ablation for the Treatment of Paroxysmal and Persistent Atrial Fibrillation | — | Heart Rhythm Clinical and Research Solutions, LLC | 8 mi |
| An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) | Phase 3 | AstraZeneca | 8 mi |
| A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | Phase 3 | Eli Lilly and Company | 8 mi |
| A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | Phase 3 | Eli Lilly and Company | 8 mi |
| Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer | Phase 3 | Genmab | 8 mi |
| A Study to Test KISIMA-02 Vaccine-based Immunotherapy and Ezabenlimab in People With Pancreatic Cancer | Phase 1 | Boehringer Ingelheim | 8 mi |
| First in Human Study of IMGN151 in Recurrent Gynaecological Cancers | Phase 1 | AbbVie | 8 mi |
| A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period. | Phase 2 | Genentech, Inc. | 8 mi |
| RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis | Phase 1/2 | Cabaletta Bio | 8 mi |
| Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide | Phase 3 | Novo Nordisk A/S | 8 mi |
| Cognitive Behavioral Intervention to Reduce Procedural Anxiety Among Woman With High Risk Pregnancies With Scheduled Cesarean Deliveries | N/A | University of Colorado, Denver | 8 mi |
| Understanding and Addressing Rejection of Personalized Breast Cancer Risk Information in Women | N/A | University of Colorado, Denver | 8 mi |
| A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor | Phase 1/2 | Eisai Inc. | 8 mi |
| Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) | Phase 3 | Advenchen Laboratories, LLC | 8 mi |
| Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes | Phase 2 | National Cancer Institute (NCI) | 8 mi |
| Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment | Phase 2 | National Cancer Institute (NCI) | 8 mi |
| Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol | Phase 1 | NRG Oncology | 8 mi |
| ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma | Phase 2 | Nationwide Children's Hospital | 8 mi |
| A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy | Phase 2 | OncoVerity, Inc. | 8 mi |
| BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study | Phase 2 | National Cancer Institute (NCI) | 8 mi |
| Study of Large Channel Digital Pancreaticobiliary Scope (DPS) With Compatible Accessories | Phase 4 | University of Colorado, Denver | 8 mi |
| Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen | Phase 3 | Servier Bio-Innovation LLC | 8 mi |
| Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma | Phase 2 | Diwakar Davar | 8 mi |
| Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis | Phase 3 | Cartesian Therapeutics | 8 mi |
| Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer | Phase 3 | GOG Foundation | 8 mi |
| A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma | Phase 2/3 | Linnaeus Therapeutics, Inc. | 8 mi |
| Development and Evaluation of a Screening Approach for Sexual Dysfunction in AYA Patients With and Surviving Childhood Cancer | N/A | University of Colorado, Denver | 8 mi |
| Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome | Phase 3 | University of Colorado, Denver | 8 mi |
| Gonadal Dysgenesis Tissue Cryopreservation for Fertility Preservation | N/A | University of Colorado, Denver | 8 mi |
| Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis | Phase 2 | NMD Pharma A/S | 8 mi |
| The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL | Phase 2 | Pediatric Transplantation & Cellular Therapy Consortium | 8 mi |
| Targeted Pediatric High-Grade Glioma Therapy | — | Nationwide Children's Hospital | 8 mi |
| Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML | Phase 1 | Stelexis BioSciences | 8 mi |
| SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) | Phase 3 | Nuvation Bio Inc. | 8 mi |
| Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation | Phase 1 | Institut de Recherches Internationales Servier | 8 mi |
| A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors) | Phase 1 | Boehringer Ingelheim | 8 mi |
| UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1 | Phase 1 | University of Colorado, Denver | 8 mi |
| A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis | Phase 2/3 | Janssen Research & Development, LLC | 8 mi |
| A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer. | Phase 2 | Kahr Bio Australia Pty Ltd | 8 mi |
| Efficacy and Safety of the CG-100 Intraluminal Bypass Device | N/A | Colospan Ltd. | 8 mi |
| Phase I/IB Trial of Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma | Phase 1/2 | University of Colorado, Denver | 8 mi |
| Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma | Phase 2 | University of Colorado, Denver | 8 mi |
| GCC19CART for Patients With Metastatic Colorectal Cancer | Phase 1 | Lyell Immunopharma, Inc. | 8 mi |
| Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia | Phase 1 | St. Jude Children's Research Hospital | 8 mi |
| A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors | Phase 2 | Nationwide Children's Hospital | 8 mi |
| Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02) | Phase 1/2 | Merck Sharp & Dohme LLC | 8 mi |
| High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers | Phase 2 | VA Office of Research and Development | 8 mi |
| A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma | Phase 2 | Acrivon Therapeutics | 8 mi |
| NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial | Phase 2 | New Approaches to Neuroblastoma Therapy Consortium | 8 mi |
| Collecting Blood and Stool Samples to Detect Colorectal Cancer or Advanced Neoplasia in Lynch Syndrome Patients | — | Mayo Clinic | 8 mi |
| Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC) | Phase 3 | Polaris Group | 8 mi |
| Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors | Phase 1/2 | MBrace Therapeutics | 8 mi |
| A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss | Phase 3 | Children's Oncology Group | 8 mi |
| Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas | Phase 1 | Inhibrx Biosciences, Inc | 8 mi |
| A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) | Phase 2 | Merck Sharp & Dohme LLC | 8 mi |
| Collection of Tissue Samples for Cancer Research | — | National Cancer Institute (NCI) | 8 mi |
| (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis | Phase 2/3 | Blueprint Medicines Corporation | 8 mi |
| Impact of Chemotherapy on Urinary Biomarkers and Non-Invasive Urodynamics in Children | — | University of Colorado, Denver | 8 mi |
| UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL | Phase 1/2 | University of Colorado, Denver | 8 mi |
| The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis | N/A | Ad scientiam | 8 mi |
| A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy | Phase 1 | Children's Oncology Group | 8 mi |
| CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL | Phase 1 | University of Colorado, Denver | 8 mi |
| A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma | Phase 3 | Bristol-Myers Squibb | 8 mi |
| ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas | Phase 2 | Nationwide Children's Hospital | 8 mi |
| Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates | Phase 2 | University of Colorado, Denver | 8 mi |
| Study of Olutasidenib and Temozolomide in HGG | Phase 2 | Rigel Pharmaceuticals | 8 mi |
| Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution | — | Children's Hospital Medical Center, Cincinnati | 8 mi |
| BfedBwell Optimization Pilot | N/A | University of Colorado, Denver | 8 mi |
| Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma | Phase 1/2 | St. Jude Children's Research Hospital | 8 mi |
| First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma | Phase 1/2 | Adcendo ApS | 8 mi |
| Early Diagnosis of Pancreatic Cancer Duodenal Fluid-Based Biomarker Exploratory Study | — | Do Hyun Park | 8 mi |
| CNS Qualitative Interview | — | University of Colorado, Denver | 8 mi |
| Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma | Phase 3 | National Cancer Institute (NCI) | 8 mi |
| Shwachman Diamond Syndrome Registry and Study | — | Boston Children's Hospital | 8 mi |
| Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia | Phase 1 | University of Colorado, Denver | 8 mi |
| Lynch Syndrome Integrative Epidemiology and Genetics | — | University of Colorado, Denver | 8 mi |
| Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma. | Phase 3 | Iovance Biotherapeutics, Inc. | 8 mi |
| Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients | Phase 1 | University of Colorado, Denver | 8 mi |
| A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas | Phase 1 | Antengene Biologics Limited | 8 mi |
| Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors | Phase 1 | BeOne Medicines | 8 mi |
| A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer | Phase 1/2 | Janssen Research & Development, LLC | 8 mi |
| Sustaining Physical Activity After Cancer Exercise Sessions | N/A | Colorado State University | 8 mi |
| Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | Phase 1/2 | ModernaTX, Inc. | 8 mi |
| A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) | Phase 2 | National Cancer Institute (NCI) | 8 mi |
| Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial | Phase 2 | National Cancer Institute (NCI) | 8 mi |
| Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo) | Phase 3 | PharmaMar | 8 mi |
| Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma | Phase 1 | Children's Oncology Group | 8 mi |
| A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study | Phase 2 | Children's Oncology Group | 8 mi |
| Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma | Phase 1 | SciTech Development, Inc. | 8 mi |
| Colonoscopy vs Stool Testing for Older Adults With Colon Polyps | N/A | Dartmouth-Hitchcock Medical Center | 8 mi |
| Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies | Phase 1/2 | Replimune Inc. | 8 mi |
| To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL | Phase 3 | Acrotech Biopharma Inc. | 8 mi |
| A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) | Phase 1 | Hoffmann-La Roche | 8 mi |
| Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT | Phase 3 | Priothera SAS | 8 mi |
| Contrast Enhanced Ultrasound in Neurosurgery to Improve Glioma Visualization and Border Demarcation | Early 1 | University of Colorado, Denver | 8 mi |
| A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma | Phase 2/3 | Global Coalition for Adaptive Research | 8 mi |
| A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma | Phase 1 | Hoffmann-La Roche | 8 mi |
| The Intersection of Oncology Care and Worker Well-Being | — | University of Colorado, Denver | 8 mi |
| Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) | Phase 3 | PedAL BCU, LLC | 8 mi |
| A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers | Phase 1/2 | Regeneron Pharmaceuticals | 8 mi |
| Wide-Area Transepithelial Sampling in Endoscopic Eradication Therapy for Barrett's Esophagus | N/A | Northwestern University | 8 mi |
| Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia | Phase 1 | Nerviano Medical Sciences | 8 mi |
| A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer | Phase 3 | AstraZeneca | 8 mi |
| Patient Preferences for Barrett's Esophagus and Esophageal Cancer Screening Tests | — | University of Colorado, Denver | 8 mi |
| A Study of CHS-114 in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors | Phase 1 | Coherus Oncology, Inc. | 8 mi |
| A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT | Phase 2 | Children's Oncology Group | 8 mi |
| Microbiome in Head and Neck Squamous Cell Carcinoma | — | University of Colorado, Denver | 8 mi |
| A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma | Phase 1 | AbbVie | 8 mi |
| Psilocybin Therapy in Advanced Cancer | Phase 2/3 | NYU Langone Health | 8 mi |
| Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma | Phase 2/3 | Daiichi Sankyo | 8 mi |
| Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL) | Phase 1/2 | SWOG Cancer Research Network | 8 mi |
| Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia | N/A | University of Colorado, Denver | 8 mi |
| ALIGN for Older Adults With Cancer in SNFs | N/A | University of Colorado, Denver | 8 mi |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s) | Phase 1 | Hoffmann-La Roche | 8 mi |
| CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma | Phase 1 | Caribou Biosciences, Inc. | 8 mi |
| Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma | Phase 3 | National Cancer Institute (NCI) | 8 mi |
| A Study of ZN-c3 in Patients With Ovarian Cancer | Phase 1 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | 8 mi |
| Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma | Phase 1 | National Cancer Institute (NCI) | 8 mi |
| A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) | Phase 3 | GlaxoSmithKline | 8 mi |
| Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer | Phase 1 | National Cancer Institute (NCI) | 8 mi |
| FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC | Phase 2/3 | Bicara Therapeutics | 8 mi |
| Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas | Phase 1 | Children's Hospital of Philadelphia | 8 mi |
| A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) | Phase 3 | Merck Sharp & Dohme LLC | 8 mi |
| REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors | N/A | Dana-Farber Cancer Institute | 8 mi |
| Evaluation of Pancreatic Cystic Lesions Via EUS-guided Fine Needle Aspiration With and Without Micro Forceps Biopsies | N/A | University of Colorado, Denver | 8 mi |
| Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant | Phase 2 | Nationwide Children's Hospital | 8 mi |
| Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors | Phase 1/2 | Nationwide Children's Hospital | 8 mi |
| A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) | Phase 1/2 | Merck Sharp & Dohme LLC | 8 mi |
| MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma | Phase 2 | Nationwide Children's Hospital | 8 mi |
| Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants | Phase 1 | Iovance Biotherapeutics, Inc. | 8 mi |
| A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma | Phase 2 | Hoffmann-La Roche | 8 mi |
| PCOM2 - The Physician Communication Intervention, Version 2.0 | N/A | University of Colorado, Denver | 8 mi |
| A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion | Early 1 | Nationwide Children's Hospital | 8 mi |
| A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02) | Phase 3 | AstraZeneca | 8 mi |
| Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors | Phase 1/2 | Immunocore Ltd | 8 mi |
| A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 3 | National Cancer Institute (NCI) | 8 mi |
| Carboplatin or Olaparib for BRcA Deficient Prostate Cancer | Phase 2 | VA Office of Research and Development | 8 mi |
| Relationships Between Physical Activity and Different Measures of Fatigue in Cancer Survivors | — | University of Colorado, Denver | 8 mi |
| A Study of EBC-129 in Advanced Solid Tumours | Phase 1 | EDDC (Experimental Drug Development Centre), A*STAR Research Entities | 8 mi |
| Study of TJ033721 (givastomig) in Subjects with Advanced or Metastatic Solid Tumors | Phase 1 | I-Mab Biopharma US Limited | 8 mi |
| A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | Phase 3 | Celgene | 8 mi |
| Shareholder-driven Co-design and Piloting of Spanish Educational Videos About High Yield Pediatric Oncology Topics | N/A | University of Colorado, Denver | 8 mi |
| Neuroblastoma Biology Study | — | New Approaches to Neuroblastoma Therapy Consortium | 8 mi |
| Couple-Based Mindfulness Intervention for Metastatic Colorectal Cancer | — | University of Colorado, Denver | 8 mi |
| A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) | Phase 1/2 | Nuvalent Inc. | 8 mi |
| CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma | Phase 1/2 | Children's Oncology Group | 8 mi |
| A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations | Phase 1/2 | Turning Point Therapeutics, Inc. | 8 mi |
| CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer | Phase 1 | National Cancer Institute (NCI) | 8 mi |
| Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma | Phase 1 | Institut de Recherches Internationales Servier | 8 mi |
| Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma | Phase 3 | European Organisation for Research and Treatment of Cancer - EORTC | 8 mi |
| A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | Phase 3 | AbbVie | 8 mi |
| Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA with High Risk T-Cell ALL & Lymphoma | Phase 1 | New York Medical College | 8 mi |
| A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST) | Phase 1/2 | Deciphera Pharmaceuticals, LLC | 8 mi |
| An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib | Phase 2 | University of Colorado, Denver | 8 mi |
| Improving Communication and Building a Stronger Medical Home Among Spanish-speaking Families | — | University of Colorado, Denver | 8 mi |
| A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers | Phase 1 | Janssen Research & Development, LLC | 8 mi |
| Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas | Phase 3 | National Cancer Institute (NCI) | 8 mi |
| A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) | Phase 1/2 | Merck Sharp & Dohme LLC | 8 mi |
| Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) | Phase 1/2 | Merck Sharp & Dohme LLC | 8 mi |
| Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study | Phase 2 | Hoffmann-La Roche | 8 mi |
| Pan Tumor Rollover Study | Phase 2 | Bristol-Myers Squibb | 8 mi |
| Implementation of a ColoRectal Cancer Screening Tool in US Primary Care Practices - Usual Quality Improvement (10 Clinics) vs Normalization Process Theory-Participatory Learning in Action (10 Clinics) | N/A | University of Kansas Medical Center | 8 mi |
| Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors | Phase 1 | SystImmune Inc. | 8 mi |
| Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma | Phase 1/2 | Children's Oncology Group | 8 mi |
| Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617 | Phase 1/2 | Pathos AI, Inc. | 8 mi |
| Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma | Phase 2 | Jazz Pharmaceuticals | 8 mi |
| A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011) | Phase 2 | Merck Sharp & Dohme LLC | 8 mi |
| Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma | Phase 1 | Shyam S.D. Rao | 8 mi |
| Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis | Phase 2 | Telios Pharma, Inc. | 8 mi |
| Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial | Phase 2 | National Cancer Institute (NCI) | 8 mi |
| Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis | Phase 1 | University of Colorado, Denver | 8 mi |
| A Study to Give Treatment Inside the Eye to Treat Retinoblastoma | Phase 2 | Children's Oncology Group | 8 mi |
| A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) | Phase 3 | BeiGene | 8 mi |
| Childhood Cancer Survivor Study | — | St. Jude Children's Research Hospital | 8 mi |
| Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) | Phase 3 | Merck Sharp & Dohme LLC | 8 mi |
| DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2) | Phase 3 | Day One Biopharmaceuticals, Inc. | 8 mi |
| A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG) | Phase 1/2 | National Cancer Institute (NCI) | 8 mi |
| Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer | Phase 1/2 | National Cancer Institute (NCI) | 8 mi |
| Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX) | Phase 3 | Mayo Clinic | 8 mi |
| Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer | Phase 1 | Amgen | 8 mi |
| Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) | Phase 1/2 | Merck Sharp & Dohme LLC | 8 mi |
| A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors | Phase 1 | Genentech, Inc. | 8 mi |
| Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas | Phase 2 | University of Colorado, Denver | 8 mi |
| A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation | Phase 1/2 | Syndax Pharmaceuticals | 8 mi |
| A Study of JNJ-87189401 Plus JNJ-78278343 for Advanced Prostate Cancer | Phase 1 | Janssen Research & Development, LLC | 8 mi |
| A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT) | Phase 3 | Children's Oncology Group | 8 mi |
| Pediatric Oncology Recovery Trial After Surgery | — | University of Colorado, Denver | 8 mi |
| Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer | Phase 4 | Novartis Pharmaceuticals | 8 mi |
| Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia | Phase 2 | National Cancer Institute (NCI) | 8 mi |
| A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01) | Phase 1/2 | Merck Sharp & Dohme LLC | 8 mi |
| A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors | Phase 3 | BeOne Medicines | 8 mi |
| Patient-Reported Outcomes and Quality of Life in Adult and Pediatric Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL) | — | St. Jude Children's Research Hospital | 8 mi |
| SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma | Phase 3 | Immatics US, Inc. | 8 mi |
| Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance | N/A | University of Colorado, Denver | 8 mi |
| A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Loxo Oncology, Inc. | 8 mi |
| A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma | Phase 2 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 8 mi |
| Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms | N/A | Case Comprehensive Cancer Center | 8 mi |
| Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors | Phase 1/2 | Revolution Medicines, Inc. | 8 mi |
| A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors | Phase 1/2 | Bristol-Myers Squibb | 8 mi |
| Collection and Storage of Tissue and Blood Samples From Patients With Cancer | — | National Cancer Institute LAO | 8 mi |
| PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma | Phase 2 | Nationwide Children's Hospital | 8 mi |
| Cladribine Venetoclax in Monocytic AML | Phase 2 | University of Colorado, Denver | 8 mi |
| Losartan + Sunitinib in Treatment of Osteosarcoma | Phase 1 | University of Colorado, Denver | 8 mi |
| A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients | Phase 3 | Children's Oncology Group | 8 mi |
| A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103) | Phase 1 | Amgen | 8 mi |
| Accuracy of Continuous Glucose Monitors During the Perioperative Period in Youth With Type 1 Diabetes | — | University of Colorado, Denver | 8 mi |
| Pathogenesis of Kidney Disease in Type 1 Diabetes: a Modern Kidney Biopsy Cohort (The PANDA Study) | — | University of Colorado, Denver | 8 mi |
| GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes | N/A | Medtronic Diabetes | 8 mi |
| CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D) | Phase 1/2 | COUR Pharmaceutical Development Company, Inc. | 8 mi |
| Type 1 Diabetes Extension Study | — | National Institute of Allergy and Infectious Diseases (NIAID) | 8 mi |
| SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes | Phase 2 | SAb Biotherapeutics, Inc. | 8 mi |
| Type 1 Diabetes REst for Metabolic Health | N/A | University of Colorado, Denver | 8 mi |
| A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma | Phase 2 | Children's Oncology Group | 8 mi |
| Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study) | — | Petter Bjornstad | 8 mi |
| Primary Care Pragmatic, Real World Experience for Automated Insulin Delivery | N/A | University of Colorado, Denver | 8 mi |
| Treating Early Type 2 Diabetes by Reducing Postprandial Glucose Excursions: A Paradigm Shift in Lifestyle Modification | N/A | Chiara Fabris, PhD | 8 mi |
| Breaking up Sedentary Time to Improve Glucose Control in a Population at Risk for Developing Type 2 Diabetes | Early 1 | University of Colorado, Denver | 8 mi |
| EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease | Phase 3 | Boehringer Ingelheim | 8 mi |
| Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes | Phase 3 | Kailera | 8 mi |
| FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy (FABULINUS) | Phase 2 | Sanofi | 8 mi |
| Inhaled Insulin vs Rapid-acting Injections for Post-meal Glucose Control in Women With Gestational Diabetes | Phase 2/3 | Jaeb Center for Health Research | 8 mi |
| Registry for Stage 2 Type 1 Diabetes | — | Sanofi | 8 mi |
| Using Simplified Meal Boluses Versus Carbohydrate Counting in Adolescents With Hybrid Closed Loop Systems | N/A | University of Colorado, Denver | 8 mi |
| Effect of Montelukast on Kidney and Vascular Function in Type 1 Diabetes | Phase 4 | University of Colorado, Denver | 8 mi |
| Colorado Community Engagement Alliance | — | University of Colorado, Denver | 8 mi |
| Role of Microvascular Insulin Resistance and Cardiorespiratory Fitness Diabetes | N/A | University of Colorado, Denver | 8 mi |
| Rare and Atypical Diabetes Network | — | University of South Florida | 8 mi |
| GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance | Phase 2 | University of Pennsylvania | 8 mi |
| A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes | Phase 3 | Eli Lilly and Company | 8 mi |
| Efficacy and Mechanisms of Dapagliflozin in Promoting Kidney Function and Cardiovascular Health in Kidney Transplant Recipients | Phase 4 | University of Colorado, Denver | 8 mi |
| Precision Administration of Anti-thymocyte Globulin With or Without Verapamil | Phase 2 | University of Florida | 8 mi |
| Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM) | — | Jaeb Center for Health Research | 8 mi |
| Impact of MEnstruation on Glycemic Response and Exercise In Females With Type 1 Diabetes | N/A | University of Colorado, Denver | 8 mi |
| Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes | Phase 3 | University of Colorado, Denver | 8 mi |
| MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes | Phase 1 | Kalie Tommerdahl | 8 mi |
| Renal Mechanism of SGLT2 Inhibition | Phase 2 | University of Colorado, Denver | 8 mi |
| AIDANET Pediatrics | N/A | Mark D. DeBoer, MD, MSc., MCR | 8 mi |
| Pancreas Ultrasound Imaging in type1 Diabetes | — | University of Colorado, Denver | 8 mi |
| Optimizing Gait Rehabilitation for Veterans With Non-traumatic Lower Limb Amputation | N/A | VA Office of Research and Development | 8 mi |
| Supporting VETerans With Kidney Disease Through Food As Medicine | N/A | VA Eastern Colorado Health Care System | 8 mi |
| Glucose Monitoring in Youth With Cystic Fibrosis During Pulmonary Exacerbations | — | University of Colorado, Denver | 8 mi |
| T1D Pregnancy & Me | — | Jaeb Center for Health Research | 8 mi |
| A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease | Phase 2 | Novo Nordisk A/S | 8 mi |
| Fitbit and AI Chatbot in Sedentary Primary Care Patients With T2D | — | University of Colorado, Denver | 8 mi |
| DISCOVERY of Risk Factors for Type 2 Diabetes in Youth | — | George Washington University | 8 mi |
| Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes | Phase 2 | University of Washington | 8 mi |
| INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes | Phase 2 | Mannkind Corporation | 8 mi |
| PRenatal and Obstetric Maternal Exposures and ISlet Autoantibodies in Early Life | — | University of Colorado, Denver | 8 mi |
| Bionic Pancreas in CFRD | Phase 3 | Jaeb Center for Health Research | 8 mi |
| TArgeting Type 1 Diabetes Using POLyamines (TADPOL) | Phase 2 | Emily K. Sims | 8 mi |
| Computerized Cognitive Behavioral Therapies for Suicide Prevention and Depression | Phase 2 | VA Eastern Colorado Health Care System | 8 mi |
| Cognitive-Behavioral Therapy and Exercise Training in Adolescents At-Risk for Type 2 Diabetes | N/A | Colorado State University | 8 mi |
| NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | Phase 3 | Neurocrine Biosciences | 8 mi |
| CBD for Individuals at Risk for Alzheimer's Disease | Phase 2 | University of Colorado, Denver | 8 mi |
| Trial-Ready Cohort-Down Syndrome (TRC-DS) | — | University of Southern California | 8 mi |
| Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease | Phase 2 | Celgene | 8 mi |
| Intervention to Collect and Utilize Sexual Orientation and Gender Identity (SOGI) Information in Hospice | N/A | University of Colorado, Denver | 8 mi |
| Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer's Disease | Phase 2 | University of Colorado, Denver | 8 mi |
| Cardiometabolic Consequences of the Loss of Ovarian Function | Phase 4 | University of Colorado, Denver | 8 mi |
| A Pilot Factorial Trial of an Integrated Lifestyle Intervention | N/A | University of Colorado, Denver | 8 mi |
| Bone, Exercise, Alendronate, and Caloric Restriction | Phase 4 | Wake Forest University Health Sciences | 8 mi |
| Neuronal and Behavioral Effects of an Implicit Priming Approach to Improve Eating Behaviors in Obesity | N/A | University of Colorado, Denver | 8 mi |
| Early vs. Late Time Restricted Eating vs. Daily Caloric Restriction | N/A | University of Colorado, Denver | 8 mi |
| Behavioral Weight Loss and Sleep Health Intervention | N/A | University of Colorado, Denver | 8 mi |
| Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents | Phase 1 | University of Colorado, Denver | 8 mi |
| Effect of Weight Loss on Intermuscular Adipose Tissue (IMAT) Signaling | N/A | University of Colorado, Denver | 8 mi |
| Timing Intervention of Morning Versus Evening Exercise | N/A | University of Colorado, Denver | 8 mi |
| HealthyTogether: RCT of a Dyadic Weight Management Intervention | N/A | VA Office of Research and Development | 8 mi |
| Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant | Phase 3 | Eidos Therapeutics, a BridgeBio company | 8 mi |
| Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS | Phase 3 | DalCor Pharmaceuticals | 8 mi |
| North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC) | — | Columbia University | 8 mi |
| A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM) | — | Bristol-Myers Squibb | 8 mi |
| The Long-term Safety and Effectiveness Evaluation of the QDOT MICRO System Use in Conjunction With VISITAG SURPOINT Module for the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation. | — | Heart Rhythm Clinical and Research Solutions, LLC | 8 mi |
| Implementation of an Algorithm- and Multi-professional Team-supported Strategy to Improve Lipid Management of Patients With Atherosclerotic Cardiovascular Disease | N/A | Colorado Prevention Center | 8 mi |
| Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ) | Phase 3 | NYU Langone Health | 8 mi |
| Autus Valve Pivotal Study | N/A | Autus Valve Technologies, Inc. | 8 mi |
| Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease | Phase 3 | Alessandro Doria | 8 mi |
| Implementation and Interaction of Clinician And Patient-facing Tools Aiming to Intensify Neurohormonal Medicines for Heart Failure | N/A | University of Colorado, Denver | 8 mi |
| Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy | Phase 4 | Dennis M. McNamara, MD, MS | 8 mi |
| Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG | Phase 3 | Icahn School of Medicine at Mount Sinai | 8 mi |
| Digital Health Physical Activity Program for Older Family Care Partners of Patents With Heart Failure | N/A | University of Colorado, Denver | 8 mi |
| Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes | Phase 4 | VA Office of Research and Development | 8 mi |
| Evaluating the Reach of Clinical Decision Support for Patients With Heart Failure | N/A | University of Colorado, Denver | 8 mi |
| International Spontaneous Coronary Artery Dissection (SCAD) "iSCAD" Registry | — | SCAD Alliance | 8 mi |
| CardioHeartConnect: Commercially Available Fitness for Cardiac Rehabilitation | N/A | University of Colorado, Denver | 8 mi |
| Optimizing Pulsatility During Cardiopulmonary Bypass | — | University of Colorado, Denver | 8 mi |
| A Study to Learn About The COVID-19 (Study) Vaccine (Called COMIRNATY) in People That Are Less Than 21 Years Old. | Phase 4 | Pfizer | 8 mi |
| Fresh Autologous Whole Blood Transfusion After Cardiopulmonary Bypass | N/A | University of Colorado, Denver | 8 mi |
| Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women | N/A | Weill Medical College of Cornell University | 8 mi |
| Safety and Efficacy of Workflows of High Volume Single Operators in a LAAO Device Implant Procedural Day | — | Heart Rhythm Clinical and Research Solutions, LLC | 8 mi |
| Anticoagulation in ICH Survivors for Stroke Prevention and Recovery | Phase 3 | Yale University | 8 mi |
| A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study) | Phase 2 | Tectonic Therapeutic | 8 mi |
| A Study of Assessment on Safety and Effectiveness of BWI Pulsed Field Ablation With OMNYPULSE Catheter for the Treatment of Paroxysmal Atrial Fibrillation (PAF) | N/A | Biosense Webster, Inc. | 8 mi |
| Danon Disease Natural History Study | — | Rocket Pharmaceuticals Inc. | 8 mi |
| National Collaborative to Improve Care of Children With Complex Congenital Heart Disease | — | Children's Hospital Medical Center, Cincinnati | 8 mi |
| Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy | — | Tenaya Therapeutics | 8 mi |
| Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight Infants | N/A | Nationwide Children's Hospital | 8 mi |
| Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036) | Phase 2/3 | Merck Sharp & Dohme LLC | 8 mi |
| Pediatric Prehospital Airway Resuscitation Trial | N/A | Ohio State University | 8 mi |
| COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction | N/A | Edwards Lifesciences | 8 mi |
| Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated ARVC | Phase 1 | Tenaya Therapeutics | 8 mi |
| Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) | — | Tenaya Therapeutics | 8 mi |
| Optimal Pediatric Heart Transplant Immunosuppression With MicroRNAs | — | Inova Health Care Services | 8 mi |
| Minima Stent System Post- Approval Study (PAS) | — | Renata Medical | 8 mi |
| Inspiring New Science In Guiding Healthcare in Turner Syndrome Registry | — | University of Colorado, Denver | 8 mi |
| A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction | Phase 3 | Bayer | 8 mi |
| Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present With Symptomatic Heart Failure With Reduced Ejection Fraction (HFrEF): The CORCINCH-HF Study | N/A | Ancora Heart, Inc. | 8 mi |
| Simulation Trial of Telemedical Support for Paramedics | N/A | Boston Medical Center | 8 mi |
| A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy | Phase 2 | Novo Nordisk A/S | 8 mi |
| Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | Phase 3 | Cytokinetics | 8 mi |
| A Basket Study of Vosoritide in Children With Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, and Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment | Phase 2 | BioMarin Pharmaceutical | 8 mi |
| Quality of Pediatric Resuscitation in a Multicenter Collaborative | — | Children's Hospital of Philadelphia | 8 mi |
| Starlight Cardiovascular Lifeline Ductus Arteriosus Stent IDE Study | N/A | Starlight Cardiovascular Inc | 8 mi |
| Obesity, Metabolic Dysregulation and the Airway Epithelium in Asthmatics | N/A | University of Colorado, Denver | 8 mi |
| Registry of Asthma Characterization and Recruitment 3 (RACR3) | — | National Institute of Allergy and Infectious Diseases (NIAID) | 8 mi |
| Navigating Together for Equitable Asthma Management for Children in Families Who Communicate in Language Other Than English | N/A | University of Colorado, Denver | 8 mi |
| Anti Inflammatory Lipid Mediators in Asthma Lipid Anti-Inflammtory Mediators in Asthma | Phase 2 | University of Colorado, Denver | 8 mi |
| Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | — | Duke University | 8 mi |
| Protocol CAUSE-03 / CHEETAH | — | National Institute of Allergy and Infectious Diseases (NIAID) | 8 mi |
| Individualizing Treatment for Asthma in Primary Care (Full Study) | Phase 4 | DARTNet Institute | 8 mi |
| Expanding Exercise Programming for Veterans Through Telehealth | N/A | VA Office of Research and Development | 8 mi |
| Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry | — | Duke University | 8 mi |
| Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis | Phase 1 | Sonoma Biotherapeutics, Inc. | 8 mi |
| Knee Osteoarthritis Rehabilitation Through Rotational Inertia | N/A | University of Colorado, Denver | 8 mi |
| Evaluating Changes in Synovial Fluid Before and After GAE for Knee Osteoarthritis | N/A | University of Colorado, Denver | 8 mi |
| Rheumatoid Arthritis Patients at Risk for Interstitial Lung Disease | — | University of Colorado, Denver | 8 mi |
| A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic | — | Sonoma Biotherapeutics, Inc. | 8 mi |
| At-home Ultrasound Localized Therapy for Rheumatoid Arthritis Study [At-home ULTRA Study] | N/A | SecondWave Systems Inc. | 8 mi |
| Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease | — | University of Colorado, Denver | 8 mi |
| Non-invasive Evaluation of Upper and Lower Body Function With Showmotion | N/A | University of Colorado, Denver | 8 mi |
| Open Access Database of Standing Full Body Radiographs in Asymptomatic Volunteers | N/A | University of Colorado, Denver | 8 mi |
| Identifying Right Ventricular Dysfunction in COPD Through Right Heart Catheterization, Imaging and Exercise | N/A | University of Colorado, Denver | 8 mi |
| Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH | Phase 2 | VA Office of Research and Development | 8 mi |
| A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD | Phase 2 | Upstream Bio Inc. | 8 mi |
| TIDES 2.0: Prevalence and Longitudinal Course of Depression, Anxiety, and Behavior Problems in Children With Cystic Fibrosis Under 12 Years of Age | — | State University of New York at Buffalo | 8 mi |
| Preventing Maternal Mood, Anxiety, and Trauma Symptoms After Cesarean Delivery | N/A | University of Colorado, Denver | 8 mi |
| The Development of PATH, a Program to Support NICU Parent Mental Health Through the Transition From Hospital to Home | N/A | University of Colorado, Denver | 8 mi |
| A Comparison of Two School Based Interventions to Manage Anxiety in Autistic Students | N/A | University of Colorado, Denver | 8 mi |
| Collaborative Care for Treatment of Depression and Anxiety | — | Kaiser Permanente | 8 mi |
| REVEAL Study - Diagnostic Testing for PTSD Using the Senseye Diagnostic Tool | Phase 3 | Senseye, Inc. | 8 mi |
| Modulating Exercise Dosage to Improve Concussion Recovery | Phase 2 | University of Colorado, Denver | 8 mi |
| Creative Arts Program to Reduce Burnout in Healthcare Professionals | N/A | University of Colorado, Denver | 8 mi |
| Pragmatic Clinic-Based Trial of a Mindfulness Based Intervention for Mood Concerns in Youth With Type 1 Diabetes | N/A | Children's National Research Institute | 8 mi |
| Whole Health in VA Mental Health: Omnis Salutis | N/A | VA Office of Research and Development | 8 mi |
| Mindfulness Application Effects on Mental Health Symptoms in Children With Severe Tinnitus and Misophonia | N/A | University of Colorado, Denver | 8 mi |
| Cannabis for Palliative Care in Cancer | Phase 2 | University of Colorado, Boulder | 8 mi |
| A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease | Phase 2 | Neuron23 Inc. | 8 mi |
| A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease | Phase 3 | BlueRock Therapeutics | 8 mi |
| Evaluation of a Decision Aid for Deep Brain Stimulation Surgery for Parkinson's Disease | N/A | University of Colorado, Denver | 8 mi |
| Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis | Phase 4 | VA Office of Research and Development | 8 mi |
| Adaptive DBS to Offset STN Dysregulation During Exercise in PD | — | University of Colorado, Denver | 8 mi |
| Parkinson's Foundation PD GENEration Genetic Registry | — | Parkinson's Foundation | 8 mi |
| PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort | — | Michael J. Fox Foundation for Parkinson's Research | 8 mi |
| Slow Wave Sleep As a Biomarker of Rehabilitation-induced Cognitive Improvement in PD | N/A | University of Colorado, Denver | 8 mi |
| Use of CereGate Therapy for Freezing of Gait in PD | N/A | CereGate Inc. | 8 mi |
| Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry | — | Boston Scientific Corporation | 8 mi |
| Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension). | Phase 3 | Novartis Pharmaceuticals | 8 mi |
| VIBRANT: VIB4920 for Active Lupus Nephritis | Phase 2 | National Institute of Allergy and Infectious Diseases (NIAID) | 8 mi |
| A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE) | Phase 2 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 8 mi |
| Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V | Phase 2 | Novartis Pharmaceuticals | 8 mi |
| A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus | Phase 3 | UCB Biopharma SRL | 8 mi |
| The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study | Phase 2 | Children's Hospital Medical Center, Cincinnati | 8 mi |
| A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases | Phase 2 | Amgen | 8 mi |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants | Phase 2 | Hoffmann-La Roche | 8 mi |
| A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus | Phase 3 | Viatris Innovation GmbH | 8 mi |
| Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis | Phase 3 | Sanofi | 8 mi |
| An Open-label Study of AZD0120 in Adults With Multiple Sclerosis | Phase 1 | AstraZeneca | 8 mi |
| Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis | Phase 4 | Novartis Pharmaceuticals | 8 mi |
| Study to Investigate Vagus Nerve Stimulation Paired With Motor Task for Remyelination and Functional Recovery | N/A | University of Colorado, Denver | 8 mi |
| Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study | Phase 2 | Darcy Krueger | 8 mi |
| Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | Phase 3 | Sanofi | 8 mi |
| Care in Multiple Sclerosis (MS) | — | NYU Langone Health | 8 mi |
| Blood Flow Restriction And Veterans With MS | N/A | VA Office of Research and Development | 8 mi |
| A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity | Phase 2 | Celgene | 8 mi |
| Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod | Phase 4 | University of Colorado, Denver | 8 mi |
| Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) | Phase 3 | National Institute of Allergy and Infectious Diseases (NIAID) | 8 mi |
| Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate) | — | Biogen | 8 mi |
| Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) | Phase 3 | AstraZeneca | 8 mi |
| A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | Phase 3 | AstraZeneca | 8 mi |
| A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer | Phase 3 | AstraZeneca | 8 mi |
| Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) | Phase 3 | Gilead Sciences | 8 mi |
| A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors | Phase 1 | Bristol-Myers Squibb | 8 mi |
| EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD) | — | Exact Sciences Corporation | 8 mi |
| Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer | Phase 1 | Olema Pharmaceuticals, Inc. | 8 mi |
| I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | Phase 2 | QuantumLeap Healthcare Collaborative | 8 mi |
| Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer. | Phase 1/2 | Criterium, Inc. | 8 mi |
| CtDNA Based MRD Testing for NAC Monitoring in TNBC | — | Personalis Inc. | 8 mi |
| A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer | Phase 2 | Puma Biotechnology, Inc. | 8 mi |
| First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors | Phase 1/2 | Eli Lilly and Company | 8 mi |
| Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer | Phase 2 | National Cancer Institute (NCI) | 8 mi |
| Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer | Phase 2 | BicycleTx Limited | 8 mi |
| The PREDICT Registry: | — | PreludeDx | 8 mi |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | Phase 2 | National Cancer Institute (NCI) | 8 mi |
| Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer | Phase 1 | University of Colorado, Denver | 8 mi |
| Interpretations and Predictions of Patient Reported Outcomes by Breast Cancer Patients | — | University of Colorado, Denver | 8 mi |
| Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer | Phase 3 | AstraZeneca | 8 mi |
| Tucatinib+Trastuzumab+Eribulin in HER2+ MBC | Phase 2 | Criterium, Inc. | 8 mi |
| Telehealth Exercise Program Evaluating Fatigue and Physical Function in Rural Cancer Survivors | Phase 2 | University of Colorado, Denver | 8 mi |
| DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE) | Phase 2 | Criterium, Inc. | 8 mi |
| A Registry for People With T-cell Lymphoma | — | Memorial Sloan Kettering Cancer Center | 8 mi |
| Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence | Phase 1 | University of Colorado, Denver | 8 mi |
| A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases | Phase 2 | Biostar Pharma, Inc. | 8 mi |
| Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors | Phase 1/2 | Revolution Medicines, Inc. | 8 mi |
| JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer | Phase 3 | University of Texas Southwestern Medical Center | 8 mi |
| Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies | Phase 1/2 | Institut de Recherches Internationales Servier | 8 mi |
| Tempus Sculptor Study: Small Cell Lung Cancer (SCLC) Observational Study | — | Tempus AI | 8 mi |
| Specimen Banking From Patients With Lung Cancer | — | University of Colorado, Denver | 8 mi |
| A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) | Phase 2 | Genentech, Inc. | 8 mi |
| A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. | Phase 1 | Pfizer | 8 mi |
| Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors | Phase 1/2 | AstraZeneca | 8 mi |
| A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. | Phase 1 | Pfizer | 8 mi |
| Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial) | Phase 2 | SWOG Cancer Research Network | 8 mi |
| Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain | Phase 3 | NRG Oncology | 8 mi |
| A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002) | Phase 1/2 | Merck Sharp & Dohme LLC | 8 mi |
| Targeted Telerehabilitation Following Curative Intent Therapy of Lung Cancer | N/A | VA Office of Research and Development | 8 mi |
| The Lung PCA: A Multi-Dimensional Atlas of Pulmonary Premalignancy | N/A | University of Colorado, Denver | 8 mi |
| A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors | Phase 1 | Seagen, a wholly owned subsidiary of Pfizer | 8 mi |
| A Study of NX-1607 in Adults With Advanced Malignancies | Phase 1 | Nurix Therapeutics, Inc. | 8 mi |
| Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors | Phase 1 | SystImmune Inc. | 8 mi |
| A Phase 1/1b Study of IAM1363 in HER2 Cancers | Phase 1 | Iambic Therapeutics, Inc | 8 mi |
| MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma | Phase 3 | AstraZeneca | 8 mi |
| A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements | Phase 1/2 | Turning Point Therapeutics, Inc. | 8 mi |
| ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation | — | Guardant Health, Inc. | 8 mi |
| Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements | Phase 1/2 | Joshua Palmer | 8 mi |
| Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers | — | University of Colorado, Denver | 8 mi |
| Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy | — | University of Colorado, Denver | 8 mi |
| Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors | Phase 1 | SystImmune Inc. | 8 mi |
| Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability | Phase 3 | NRG Oncology | 8 mi |
| Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial) | Phase 2 | SWOG Cancer Research Network | 8 mi |
| A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer | Phase 1/2 | Volastra Therapeutics, Inc. | 8 mi |
| Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung Cancer | — | University of Colorado, Denver | 8 mi |
| Biomarker Platform (Virtual Nodule Clinic) for the Management of Indeterminate Pulmonary Nodules | N/A | Vanderbilt-Ingram Cancer Center | 8 mi |
| RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses | Phase 2 | Reunion Neuroscience Inc | 8 mi |
| Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis | Phase 3 | Zydus Therapeutics Inc. | 8 mi |
| A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD) | — | Target PharmaSolutions, Inc. | 8 mi |
| A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition | Phase 2 | Regeneron Pharmaceuticals | 8 mi |
| Liver Disease in Urea Cycle Disorders | — | Baylor College of Medicine | 8 mi |
| Study of Choline Chloride for Injection in Adolescent and Adult Patients With Intestinal Failure Receiving Long Term Parenteral Support | Phase 2/3 | Protara Therapeutics | 8 mi |
| Effect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study) | Phase 3 | University of Colorado, Denver | 8 mi |
| Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection | Phase 2 | Gilead Sciences | 8 mi |
| Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs | — | European Foundation for Study of Chronic Liver Failure | 8 mi |
| Genetic Collection Protocol | — | Arbor Research Collaborative for Health | 8 mi |
| TReatment for ImmUne Mediated PathopHysiology | Phase 2 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 8 mi |
| An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency | Phase 1/2 | iECURE, Inc. | 8 mi |
| A Prospective Database of Infants With Cholestasis | — | Arbor Research Collaborative for Health | 8 mi |
| Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US) | — | Mirum Pharmaceuticals, Inc. | 8 mi |
| Primary Sclerosing Cholangitis in Children | — | Arbor Research Collaborative for Health | 8 mi |
| A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis | Phase 2 | Mirum Pharmaceuticals, Inc. | 8 mi |
| Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection | — | University of Colorado, Denver | 8 mi |
| A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma | Phase 1/2 | Tvardi Therapeutics, Incorporated | 8 mi |
| Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | Phase 1/2 | Children's Oncology Group | 8 mi |
| Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI | N/A | VA Office of Research and Development | 8 mi |
| Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before Surgery | Phase 2 | National Cancer Institute (NCI) | 8 mi |
| DESTINY-PANTUMOUR04 | — | AstraZeneca | 8 mi |
| Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial | Phase 3 | ECOG-ACRIN Cancer Research Group | 8 mi |
| Using CTA Measures to Define Cardiac Risk In NFL Alumni | — | HeartFlow, Inc. | 9 mi |
| Integrated Cancer Repository for Cancer Research | — | University of Nebraska | 9 mi |
| Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread | Phase 2 | Gilead Sciences | 9 mi |
| A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) | Phase 2 | Merck Sharp & Dohme LLC | 9 mi |
| OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events | Phase 3 | Amgen | 9 mi |
| Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023) | Phase 2 | Merck Sharp & Dohme LLC | 9 mi |
| GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study | N/A | W.L.Gore & Associates | 9 mi |
| Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II | N/A | Shockwave Medical, Inc. | 9 mi |
| AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions | N/A | Boston Scientific Corporation | 9 mi |
| Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System | N/A | Boston Scientific Corporation | 9 mi |
| Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure | Phase 4 | Electrophysiology Research Foundation | 9 mi |
| The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With at Least Mild FMR | N/A | Cardiac Dimensions, Inc. | 9 mi |
| FORWARD CAD IDE Study | N/A | Shockwave Medical, Inc. | 9 mi |
| A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) | Phase 3 | Hoffmann-La Roche | 9 mi |
| A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors | Phase 2 | Jazz Pharmaceuticals | 9 mi |
| A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH | Phase 3 | 89bio, Inc. | 9 mi |
| A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis) | Phase 3 | 89bio, Inc. | 9 mi |
| Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors | Phase 1 | Exelixis | 9 mi |
| SELUTION 4 De Novo Small Vessel IDE Trial | N/A | M.A. Med Alliance S.A. | 9 mi |
| PIvotal Trial of the KARDION Cory P4 MechANical Circulatory SupporT SystEm | N/A | Kardion Inc | 9 mi |
| A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Phase 3 | Genmab | 12 mi |
| Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment | Phase 3 | National Cancer Institute (NCI) | 12 mi |
| A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer | Phase 3 | AbbVie | 12 mi |
| Clinical Outcomes Study of the Nexel Total Elbow | N/A | Zimmer Biomet | 12 mi |
| Zimmer Biomet Shoulder Arthroplasty PMCF | N/A | Zimmer Biomet | 12 mi |
| Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] | Phase 3 | Merck Sharp & Dohme LLC | 12 mi |
| This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1. | Phase 3 | Pfizer | 12 mi |
| Prospective Study to Assess a Diagnostic Aid for Cancer | — | Harbinger Health | 13 mi |
| Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders | Phase 3 | Ascendis Pharma A/S | 13 mi |
| Home Based Infusions for Ocrelizumab | Phase 4 | University of Colorado, Denver | 13 mi |
| Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma | Phase 3 | Karyopharm Therapeutics Inc | 13 mi |
| A Randomized Comparison of Personalized Therapy Mgmt Based On Coronary Atherosclerotic Plaque Vs. Usual Care for Symptomatic Patients With Suspicion of CAD | N/A | Cleerly, Inc. | 14 mi |
| A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer | Phase 2 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | 14 mi |
| Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma | Phase 3 | AbbVie | 14 mi |
| A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer | Phase 2 | Ono Pharmaceutical Co. Ltd | 14 mi |
| Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies | Phase 1 | AbbVie | 14 mi |
| A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors | Phase 1/2 | Merus B.V. | 14 mi |
| A Study of YL201 in Patients With Advanced Solid Tumors | Phase 1/2 | MediLink Therapeutics (Suzhou) Co., Ltd. | 14 mi |
| Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer | Phase 1/2 | Janssen Research & Development, LLC | 14 mi |
| Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer | Phase 3 | Jazz Pharmaceuticals | 14 mi |
| A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL) | Phase 1/2 | Terns, Inc. | 14 mi |
| Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2 | Phase 3 | AstraZeneca | 14 mi |
| In Vitro Maturation of Human Eggs | N/A | Colorado Center for Reproductive Medicine | 14 mi |
| A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients | Phase 3 | Merus B.V. | 14 mi |
| Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer | Phase 1/2 | Stemline Therapeutics, Inc. | 14 mi |
| Study of INCB123667 in Subjects With Advanced Solid Tumors | Phase 1 | Incyte Corporation | 14 mi |
| Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients | Phase 1/2 | Genprex, Inc. | 14 mi |
| A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC | Phase 2 | Eikon Therapeutics | 14 mi |
| Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib | Phase 1/2 | Genprex, Inc. | 14 mi |
| Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients | Phase 3 | Summit Therapeutics | 14 mi |
| A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC | Phase 3 | AstraZeneca | 14 mi |
| A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | Phase 3 | Eli Lilly and Company | 14 mi |
| A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer | Phase 2 | Puma Biotechnology, Inc. | 14 mi |
| Persona Revision Knee System Outcomes | — | Zimmer Biomet | 18 mi |
| Study of ALTO-300 in MDD | Phase 2 | Alto Neuroscience | 19 mi |
| POLARx Post Approval Study (POLARx PAS) | N/A | Boston Scientific Corporation | 19 mi |
| Persona OsseoTi Keel Compatibility Study (Total Knee Arthroplasty) | — | Zimmer Biomet | 20 mi |
| Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma | Phase 3 | Genmab | 24 mi |
| WATER IV Prostate Cancer | N/A | PROCEPT BioRobotics | 24 mi |
| A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. | Phase 3 | Epizyme, Inc. | 24 mi |
| Adipocyte-Derived Extracellular Vesicles, Weight Loss, and Endothelial Function | N/A | University of Colorado, Boulder | 24 mi |
| Observational Study of Patients Undergoing Diagnostic Right Heart Catheterization | — | HemoCept Inc. | 24 mi |
| Detecting Changes in Arterial Blood Volume and Cardiac Efficiency | — | HemoCept Inc. | 24 mi |
| Cannabidiol and Older Adult Cannabis Users | Phase 2 | University of Colorado, Boulder | 24 mi |
| Group Exposure Workshops for Socially Anxious Undergraduates | N/A | University of Colorado, Boulder | 24 mi |
| Reducing Fatigue in People With Multiple Sclerosis by Treatment With TENS | N/A | University of Colorado, Boulder | 24 mi |
| Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM) | Phase 4 | Pfizer | 30 mi |
| MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) | Phase 3 | Pfizer | 30 mi |
| Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad) | Phase 3 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 30 mi |
| Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs. | Phase 1/2 | RayzeBio, Inc. | 30 mi |
| Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer | Phase 3 | Relay Therapeutics, Inc. | 30 mi |
| A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer | Phase 1/2 | Hoffmann-La Roche | 30 mi |
| Reducing Asthma Attacks in Disadvantaged School Children With Asthma | N/A | University of Colorado, Denver | 34 mi |
| Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma | Phase 2 | National Cancer Institute (NCI) | 46 mi |
| A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments | Phase 3 | Pfizer | 46 mi |
| Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial | Phase 2/3 | National Cancer Institute (NCI) | 46 mi |
| Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial | Phase 2 | Alliance for Clinical Trials in Oncology | 46 mi |
| Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program | Phase 3 | Alliance for Clinical Trials in Oncology | 46 mi |
| J-Valve Transfemoral Pivotal Study | N/A | JC Medical, Inc., an affiliate of Edwards Lifesciences LLC | 46 mi |
| PARTNER 3 Trial - Aortic Valve-in-Valve | N/A | Edwards Lifesciences | 46 mi |
| The ENCIRCLE Trial | N/A | Edwards Lifesciences | 46 mi |
| PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR | N/A | Edwards Lifesciences | 46 mi |
| Prevail Global Study | N/A | Medtronic Vascular | 46 mi |
| ALLIANCE AVIV: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve in Failing Aortic Bioprosthetic Valves | N/A | Edwards Lifesciences | 46 mi |
| ALT-FLOW II Trial of the Edwards APTURE Transcatheter Shunt System | N/A | Edwards Lifesciences | 46 mi |
| REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE | — | Medtronic Cardiovascular | 46 mi |
| Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial | Phase 2/3 | National Cancer Institute (NCI) | 46 mi |
| A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer | Phase 3 | Shanghai Henlius Biotech | 50 mi |
| Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer | — | M.D. Anderson Cancer Center | 50 mi |